AF does have a lot to lose if CLSN is succeeds because that would destroy his AF rule of biotech, which is that a company with a market cap of less than a certain number, I don't remember what his cut off is, but CLSN is below that, is unable to develop a cancer drug.
Good points. What you are talking about is the Feuerstein-Ratain Rule. Feuerstein has been somewhat ambivalent as to whether or not the rule applies to ThermoDox. However, there are three ranges of market cap numbers involved.
The low end number is $300 million. No companies with less than a $300 million market cap before P3 results were released ever received approval. By the way we are closing in on that number. Another is $1 billion Cap. Nearly all companies in excess of a billion received approval on their cancer drugs. In the $300 million to $1 billion range the approval were mixed.
If the pps keeps going up we may validate the Feuerstein-Ratain Rule. Maybe that is why he does not bash us. Check it out on google for more in depth information.